

Chapter 7

Medicine

| Section/Addendum | Subject/Addendum Title |
|------------------|------------------------|
|------------------|------------------------|

| | |
|-------------|---|
| 1.1 | Sexual Dysfunctions And Paraphilic Disorders |
| 1.2 | Gender Dysphoria |
| 2.1 | Clinical Preventive Services - TRICARE Basic Program Benefits |
| 2.2 | Clinical Preventive Services - TRICARE Prime And Select |
| 2.3 | Family Planning |
| 2.4 | Cervical Cancer Screening |
| 2.5 | Well-Child Care |
| 2.6 | Chelation Therapy |
| 2.7 | Hydration, Therapeutic, Prophylactic, And Diagnostic Injections And Infusions |
| 3.1 | Acute Hospital Psychiatric Care |
| 3.2 | Residential Treatment Center (RTC) Care |
| 3.3 | Substance Use Disorder (SUD) Inpatient/Residential Detoxification And Rehabilitation |
| 3.4 | Psychiatric And Substance Use Disorder (SUD) Partial Hospitalization Programs (PHPs) |
| 3.5 | Substance Use Disorders (SUDs) - General |
| 3.6 | Specific Learning Disorders |
| 3.7 | Attention-Deficit/Hyperactivity Disorder |
| 3.8 | Treatment Of Mental Disorders - General |
| 3.9 | Ancillary Inpatient Mental Health Services |
| 3.10 | Psychological Testing |
| 3.11 | Psychotherapy |
| 3.12 | Family Therapy |
| 3.13 | Psychotropic Pharmacologic Management |
| 3.14 | Collateral Visits |
| 3.15 | Eating Disorder Treatment |
| 3.16 | Intensive Outpatient Program (IOP) |
| 3.17 | Opioid Treatment Program (OTP) |

TRICARE Policy Manual 6010.57-M, February 1, 2008
Chapter 7, Medicine

| Section/Addendum | Subject/Addendum Title |
|------------------|--|
| 3.18 | Medication Assisted Treatment (MAT) |
| 4.1 | Biofeedback |
| 4.2 | Dialysis |
| 5.1 | Gastroenterology |
| 6.1 | Ophthalmological Services |
| 6.2 | Lenses (Intraocular Or Contact) And Eye Glasses |
| 6.3 | Cardiovascular Therapeutic Services |
| 7.1 | Speech Services |
| 8.1 | Special Otorhinolaryngologic Services |
| 8.2 | Hearing Aids And Hearing Aid Services |
| 8.3 | Prosthetic Hearing Devices |
| 9.1 | Electronystagmography (ENG) |
| 10.1 | Echocardiogram For Dental And Invasive Procedures |
| 11.1 | Cardiac Rehabilitation |
| 12.1 | Non-Invasive Vascular Diagnostic Studies |
| 13.1 | Pulmonary Services |
| 14.1 | Allergy Testing And Treatment |
| 15.1 | Neurology And Neuromuscular Services |
| 15.2 | Sensory Evoked Potentials (SEP) |
| 16.1 | Central Nervous System (CNS) Assessments/Tests |
| 16.2 | Health And Behavior Assessment/Intervention |
| 16.3 | Chemotherapy Administration |
| 16.4 | Education And Training For Patient Self Management |
| 17.1 | Dermatological Procedures - General |
| 18.1 | Rehabilitation - General |
| 18.2 | Physical Medicine/Therapy |
| 18.3 | Occupational Therapy |
| 18.4 | Osteopathic Manipulative Therapy |
| 18.5 | Chiropractic Manipulative Treatment (CMT) |
| 19.1 | Diagnostic Sleep Studies |
| 20.1 | Hyperbaric Oxygen (HBO) Therapy |
| 21.1 | Chronic Fatigue Syndrome (CFS) |

TRICARE Policy Manual 6010.57-M, February 1, 2008
Chapter 7, Medicine

| Section/Addendum | Subject/Addendum Title |
|-------------------------|---|
| 22.1 | Telemedicine |
| 23.1 | Augmentative Communication Devices (ACDs) |
| 24.1 | Phase I, Phase II, And Phase III Cancer Clinical Trials |
| 24.2 | Coronavirus Disease 2019 (COVID-19) Clinical Trials |
| 25.1 | Dermoscopy |
| 26.1 | Forensic Examinations Following Sexual Assault or Domestic Violence |
| 27.1 | Botulinum Toxin Injections |

